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A large number of novel disease genes have been identiﬁed by homozygosity mapping and the positional
candidate approach. In this study we used single nucleotide polymorphism (SNP) array-based, whole
genome homozygosity mapping as the ﬁrst step to a molecular diagnosis in the highly heterogeneous
muscle disease, limb girdle muscular dystrophy (LGMD). In a consanguineous family, both affected siblings
showed homozygous blocks on chromosome 15 corresponding to the LGMD2A locus. Direct sequencing of
CAPN3, encoding calpain-3, identiﬁed a homozygous deletion c.483delG (p.Ile162SerfsX17). In a sporadic
LGMD patient complete absence of caveolin-3 onWestern blot was observed. However, a mutation in CAV3
could not be detected. Homozygositymapping revealed a large homozygous block at the LGMD2I locus, and
direct sequencing of FKRP encoding fukutin-related-protein detected the common homozygous c.826
C>A (p.Leu276Ile) mutation. Subsequent re-examination of this patient’s muscle biopsy showed aberrant
a-dystroglycan glycosylation. In summary, we show that whole-genome homozygosity mapping using low
cost SNP arrays provides a fast and non-invasive method to identify disease-causing mutations in sporadic
patients or sibs from consanguineous families in LGMD2. Furthermore, this is the ﬁrst study describing that
in addition to PTRF, encoding polymerase I and transcript release factor, FKRP mutations may cause
secondary caveolin-3 deﬁciency.
 2010 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
The limb girdle muscular dystrophies (LGMD) are a clinically
and genetically heterogeneous group of primary muscle disorders
characterised by progressive weakness and wasting, predominat-
ing in muscles of the pelvic and shoulder girdle, with occasionalession numbers: FKRP mRNA,
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der CC BY-NC-ND license.involvement of the myocardium [1,5]. To date, 15 genes for auto-
somal recessive LGMD (LGMD2) have been identiﬁed. Because of
the broad phenotypic variability both within groups and within
families, delineation of genotype-phenotype correlations between
these different subtypes is challenging. The accurate diagnosis
can only be made by molecular genetic analysis, which is usually
guided by protein analysis in a muscle biopsy whenever a decrease
of any of the known LGMD2 proteins can be documented [1,5]. In
addition, in the past years muscle magnetic resonance imaging
(MRI) has been applied increasingly to determine distinct patterns
of muscle involvement, which may point to a speciﬁc genetic
subtype [3,11]. Moreover, it has been shown that it can be helpful
to consider the geographical and ethnic origin of an affected indi-
vidual in the differential diagnosis because of the occurrence of
founder mutations in some subpopulations [5]. In particular,
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disease in consanguineous families and in patients whose ancestors
originate from the same geographic area. However, the disease
causing mutations still remain undetected in a large number of
LGMD2 patients [1,12].
Recent molecular genetic studies have shown considerable
progress in the identiﬁcation of recessive disease causing genes
using the positional cloning/candidate approach by homozygosity
mapping [2,7]. By deﬁnition, homozygosity mapping, also known as
autozygosity mapping, tests the assumption that a homozygous
mutation in a recessive disease is identical by descent by segregating
twice to the affected person from a common ancestor through both
the maternal and paternal line [7]. The value of single nucleotide
polymorphism (SNP) array-based homozygosity mapping, i.e. an
indirect DNA analysis as a ﬁrst step to the identiﬁcation of a disease-
causing mutation, has recently been evaluated by Hildebrandt et al.,
who retrospectively studied 72 individuals carrying known homo-
zygous mutations and originating from both inbred and outbred
populations [7].
Here we show that SNP-array-homozygosity mapping used in
an affected individual only can guide molecular genetic testing in
LGMD2, if there is known consanguinity of the parents.
2. Materials and methods
2.1. Patients
The present study included a consanguineous Turkish family
(here called MD1) with two sibs affected with LGMD2, and another
Austrian patient (here called MD2) with sporadic LGMD and known
consanguinity of the parents. Clinical and electrophysiological
studies followed standard methods and were performed with
written informed consent and approved by the local Ethical
Committee of the Medical University of Graz, Austria.
Two healthy unrelated individuals from an outbred population
were selected as controls to compare 10 K and 250 K SNP array
data.
2.2. Muscle biopsy
A muscle biopsy specimen was obtained from the gluteus
medius muscle of patient MD2. Part of the muscle biopsy was ﬁxed
in formaldehyde and embedded in parafﬁn and the rest was rapidly
frozen in isopentane cooled in liquid nitrogen. Serial transverse
cryostat sections were processed using conventional histological
stains and histochemical reactions, as previously described [14].
Immunohistochemistry was performed for dystrophin (N-
terminus, rod domain, and C-terminus, Novocastra, UK), a-sarcogly-
can (Novocastra, UK), b-sarcoglycan (Novocastra, UK), g-sarcoglycan
(Novocastra, UK), d-sarcoglycan (Novocastra, UK), dysferlin (Novo-
castra, UK), merosin (Novocastra, UK), emerin (Novocastra, UK) on
frozen, acetone-ﬁxed sections, and later on for a-dystroglycan (clone
VIA4-1, Upstate Biotechnology, USA) on formalin ﬁxed and parafﬁn
embedded tissue.
2.3. Immunoblotting
Frozen muscle samples (w20 to 30 mg) were quickly weighed
and homogenized with 1 Laemmli buffer [9]. The samples were
incubated at 95 C for 10 min and centrifuged at 13,200 g for 1 min
before 10 ml aliquots of the supernatants (equivalent to 2.5 mg
tissue) were applied to each lane. Electrophoresis, transfer, and
immunological detection were performed as previously described
[16]. The following antibodies were used: mouse monoclonal
antibodies against caveolin-3 (Santa Cruz, USA), lamin A/C (SantaCruz, USA), telethonin (BD Biosciences, Austria), calpain-3 (Leica,
Germany) and a-dystroglycan (Millipore, Austria) as well as horse-
radish-conjugated goat anti-mouse immunoglobulins (DAKO,
Denmark).
2.4. Genotyping and identiﬁcation of homozygous regions
In order to deﬁne the molecular genetic basis of the disease
regions of homozygosity in the LGMD2 patients, a whole genome
scan using Affymetrix SNP arrays was carried out. Genomic DNA
samples from patients and unaffected sibs from families MD1 and
MD2, and a control sample were hybridized to GeneChip Human
Mapping 10 K XbaI 142 2.0 arrays (Affymetrix, Santa Clara, CA, USA)
using the protocols recommended by the manufacturer. Samples
from patient MD2, her healthy sib, and from a healthy control were
subsequently also hybridized to GeneChip Human Mapping NspI
250 K arrays. Genotypes of both array types were called using
GeneChip Genotyping Analysis Software (Version 4.1) and default
thresholds. The overall call rate of each array succeeded 95% ormore.
The SNP results of family MD1 and MD2 were then further
analyzed using a self developed Java-based tool (eHoPASA e Easy
Homozygosity Proﬁling of Affymetrix SNP Arrays) which had been
designed to quickly extract genome wide regions of homozygosity
which may harbor the disease gene. The software accepts Affymetrix
SNP array data and generates result ﬁles with homozygosity proﬁles,
as well as the underlying genotyping data for these ﬁles. Single
occurrences of genotyping failure discovered as heterozygosity, or
undetermined genotypes (“no calls”), are ignored when at least seven
neighboring genotypes on each side are homozygous [15]. We arbi-
trarily deﬁned a homozygous region on the occurrence of at least 5 or
more consecutive homozygous SNPs (10 K array) and 50 SNPs (250 K
array) by the user-selectable parameter in the program. The generated
homozygosity proﬁles were plotted across the entire human genome
using the R statistical software package [13]. In addition to other
software programs [15] our tool was adapted to quickly visualize
the LGMD2 loci by inclusion of the physical positions of the LGMD2
loci and to use the local computer infrastructure. All analyses are
based on human reference sequence HG 18 (NCBI Build 36 Version 1)
genome assembly annotations. The eHoPASA software itself and R
programming code for plotting of the homozygosity proﬁles will be
freely available for download (http://ehopasa.sourceforge.net).
2.5. Mutation analysis
All exons and exon-intron bounderies of CAPN3 [OMIM 114240]
(MD1) and CAV3 [OMIM 601253], PTRF [OMIM 603198] and FKRP
[OMIM 606596] (MD2) were screened for mutations. PCR conditions
were as follow: 20 ng of genomic DNA, 5 ml HotStarTaq Mastermix
(QIAGEN GmbH, Hilden, Germany) and primer (10 pmol each) in
a total volume of 10 ml. Cycle conditions were as follows: initial
denaturation for 12 min at 95 C; 35 cycles of 45 s denaturation at
95 C, 30 s of annealing at 57 C and30 s of primer extension at 72 C;
and a ﬁnal extension for 10 min at 72 C. PCR products were puriﬁed
with ﬁlter plates (MACHEREY-NAGEL GmbH & Co. KG, Düren,
Germany) and directly sequenced with automated sequencer using
BigDye Terminator v3.1 (ABI 3730 Genetic Analyzer, Applied Bio-
systems, Foster City, CA). Sequencing analysis was carried out using
the SeqScape Software 2.5 (Applied Biosystems, Foster City, CA).
3. Results
3.1. Family MD1
The two patients, whose healthy parents are ﬁrst cousins,
initially complained about running and walking difﬁculties and
Fig. 1. Homozygosity proﬁles. The intervals of homozygosity (blue blocks) are plotted across the genome for each individual. The chromosomal positions of thehomozygous intervals are
indicated on the x-axis, the length of each homozygosity proﬁle is deﬁned by the number of basepairs (bp). The y-axis shows the number of homozygous SNPs (NHS). The physical
positions of the LGMD2genes (subtypes 2A-2O) are included and shown in green color. a. Homozygosity proﬁles for three individuals of familyMD1and a control sample (10K-Affymetrix
SNP array), ﬁrst and second line¼ affected individuals, third line¼ unaffected sib, forth line¼ control individual with no consanguinity of the parents: no homozygous blocks can be
detected in the control individual. The arrow indicates the position of themutated gene. b. Homozygosity proﬁles (10K-Affymetrix SNP array) of patient MD2 (ﬁrst line) and her healthy
sib (second line). Because of the more distant parental relationship the number of peaks is lower than in the individuals of family MD1. The arrow indicates the position of the mutated
gene. c. Homozygosity proﬁles (250 K Affymetrix SNP array) of patient MD2 compared to a control individual with no consanguinity of the parents.
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respectively. On examination there was symmetric weakness
and wasting of the limb girdle muscles predominating in the pelvic
girdle and in the proximal lower limbs muscles with the thigh
adductors more severely affected than the quadriceps muscles.
Serum creatine kinase (CK) levels were markedly increased up to
5500 and 12,000 U/L (normal values< 170 U/L). Electromyography(EMG) showed a chronic myopathic pattern and nerve conduction
studies werewithin the normal range. These results established the
diagnosis of LGMD2.
Muscle biopsy was not done. Instead, DNA was collected from
the parents, the two patients, and the healthy sibs after informed
consent. A whole genome scan using 10 K Affymetrix SNP arrays
was carried out. We analyzed the haplotypes of the affected and
Fig. 1. (continued).
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zygosity proﬁles of each individual. As can be seen in Fig.1a, there is
only one peak present in the affected sibs which overlaps with
one of the known LGMD2 loci. This peak is located on chromosome
15 (37607895e62926989 bp) and contains the CAPN3 gene.
CAPN3 sequencing identiﬁed the known homozygous c.483delG
(p.Ile162SerfsX17) mutation in exon 3 [8] in the two affected chil-
dren, for which the parents were heterozygous (Fig. 2a). The
healthy sibs were not homozygous for this mutation.
3.2. Family MD2
At 17 years this 26 year old female ﬁrst noticed problems in
climbing stairs and weakness in the proximal upper limbs muscles
and mild to moderate cardiomyopathy appeared subsequently.
There was no family history regarding any neuromuscular diseases.
On examination calf hypertrophywas present.Muscleweakness and
wasting were restricted to the proximal limb musculature and pre-
dominated in the lower limbs. She walked with a waddling gait
and had mild scapula winging. Rippling, mounding and percussion
induced rapid muscle contractions were not present. CK levels were
elevated up to 2000 U/l and EMG conﬁrmed a chronic myopathy.
Muscle biopsy at age 23 showed severe myopathic changes
(Fig. 3aA). Caveolin-3 immunostaining and western blotting indi-
cated a complete loss of the caveolin-3 protein expression, whereas
other muscle proteins were normal (Fig. 3b). However, sequencing
of CAV3 and PTRF, which had been reported to be associated with
secondary caveolin-3 deﬁciency [6] failed to detect a pathogenic
mutation.
Subsequently, a more detailed family history revealed that the
parents of the patient were second degree cousins. Analysis of the10 K SNP array genotypes of the patient and her healthy sib
identiﬁed two large homozygous regions at chromosomes 17
(36518826e61670208 bp) and 19 (34206067e54914726 bp) cor-
responding to the LGMD2D [OMIM 608099] and LGMD2I [OMIM
607155] loci (Fig. 1b). Additional analysis of the denser 250 K SNP
array did not exclude any of these loci and did not detect further
homozygous regions corresponding to known LGMD2 loci (Fig. 1c).
Re-examination of the patient’s muscle biopsy revealed patholog-
ically aberrant glycosylation of a-dystroglycan on the sarcolemma
compared to a control muscle by immunoblotting (Fig. 3b) and
immunohistochemistry (Fig. 3aB, aC). Finally, sequencing of the
fukutin related protein gene (FKRP) identiﬁed the common c.826
C>A; (p.Leu276Ile) mutation (Fig. 2b) thus establishing the diag-
nosis of LGMD2I [17]. MRI studies of the proximal muscles of the
upper and lower limbs were consistent with previous ﬁndings in
LGMD2I [3].
4. Discussion
Individual diagnosis and classiﬁcation of LGMD2 patients is
challenging due to considerable intra- and inter-familiar clinical
variability and genetic allelic and non-allelic heterogeneity with 15
disease genes known so far. In addition, an extensive diagnostic
work-up including invasive muscle biopsy is usually required [1,5].
In this study we present the successful application of SNP-array
based whole genome homozygosity mapping in the molecular
genetic diagnosis of LGMD2. We emphasize this form of indirect
DNA analysis as the ﬁrst step in the approach to diagnose patients
from families with known or suspected parental consanguinity,
because it is fast, inexpensive, and amenable to high-throughput
setting. In principle, the causality of several known LGMD2 genes
Fig. 2. Sequences of the CAPN3 (exon 3) and the FKRP (exon 4) gene. a. Part of the pedigree of family MD1, showing the parents (ﬁrst cousins) carrying the heterozygous c.483delG
mutation (p.Ile162SerfsX17) and the two affected childrenwith the homozygous mutation, as well as one child without a sequence change at this position (see arrows). b. Part of the
sequence of patient MD2 carrying the homozygous c.826 C> A mutation; (p.Leu276Ile, rs28937900) (see arrow).
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extended homozygosity at these loci.
Because the patients included in this study originated from inbred
populations LGMD2 caused by a homozygous mutation in one of the
known LGMD2 genes was the most likely underlying genetic event.
Whole genome homozygositymapping using the 10 K SNP arraywas
straightforward in the three patients examined here. In both families
statistical and visual analysis revealed several homozygous intervals.
A single large homozygous region, at the LGMD2A [OMIM 253600]
locus, was seen in both patients from family MD1, without genetic
linkage and haplotype analyses, enabling a fast, non-invasive
diagnosis following the sequence analysis of CAPN3.
Themore distant parental relationship reduced both the number
and the size of homozygous regions in patient MD2 compared to
patients fromMD1. However, two homozygous regions overlapping
with LGMD2 loci, were considered identical by descendent from
a common ancestor because of their genomic size and extent in the
number of homozygousmarkers (Fig.1). Identiﬁcation of a common,
homozygous FKRP [17] mutation established a diagnosis of LGMD2I,Fig. 3. a. Muscle biopsy of patient MD2 shows severe myopathic changes with variation
connective tissue (asterisks) (A, H&E). Immunohistochemistry reveals a severe reduction in
control (C, a-DG). Magniﬁcation: (A) 200; (B, C) 400. b. Immunoblotting for a-DG could n
conﬁrmed the absence of caveolin 3, whereas calpain 3, lamin A/C, and telethonin were nowhich was conﬁrmed by aberrant muscle a-dystroglycan staining
(Figs. 2b and 3aB, b).
Notably, the correct diagnosis in patient MD2 was delayed due
to the absent caveolin-3 protein expression leading to the initial
suspicion of LGMD1C [OMIM 607801]. Although secondary protein
deﬁciency documented by immunohistochemistry in muscles of
LGMD patients is not unusual and may be misleading in the further
diagnostic process [12], the ﬁnding of caveolin-3 deﬁciency is
surprising, as has been demonstrated by a study suggesting that
caveolin-3 protein deﬁciency is a highly sensitive and speciﬁcmarker
of primary caveolinopathy [4]. However, secondary caveolin-3
deﬁciency has recently been reported in patients with lipodystrophy
andmuscular atrophy carryingmutations in PTRF [6]. The underlying
mechanism of the secondary caveolin-3 deﬁciency in our FKRP
patient remains elusive, butmay be due to the altered a-dystroglycan
glycosylation, which might interfere with the correct localization of
caveolin-3 at the sarcolemma. Therefore we suggest that LGMD2I
should be considered in patients with absent caveolin-3 expression
in skeletal muscle and normal results on CAV3 sequencing.in ﬁbre size (arrows), necrosis, regenerating ﬁbres, and an increase in endomysial
labelling of the glycosylated epitope of a-dystroglycan (B, a-DG) compared to healthy
ot detect the glycosylated protein with molecular mass of 150 kDa (D, a-DG, VIA4) and
rmal.
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homozygosity mapping can also successfully be applied to non-
consanguineous single individuals with rare autosomal recessive
diseases, such as LGMD2, considering the hypothesis that the disease
is caused by a homozygous mutation located within a homozygous
haplotype, being identical by descent from an unknown common
ancestor [7]. Homozygous disease-causing mutations could be
detected in single cases of outbred populations within homozygous
areas often larger than 2 Mb in size [7]. On the other hand,
homozygous genomic segments measuring up to 4 Mb were not
uncommon in individuals from outbred populations [10]. Although
application of the 10 K SNParraywas sufﬁcient to detect the disease-
related homozygous regions in the patients examined here, only
higher density SNP arrays might allow the detection of the disease-
related homozygous segments in cases of more distant or suspected
parental relationship.
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